Remember Billionaire Stanley Druckenmiller? Here Are the 3 Biggest Stocks in His Portfolio

Stanley Druckenmiller is a billionaire hedge fund manager, mainly known for being the former lead portfolio manager for George Soros’ quantum fund. He uses macroeconomic trends to make his investments and famously “broke the Bank of England” in 1992 by shorting the British pound before Black Wednesday.

George Soros hired him four years earlier to oversee Soros Fund Management. He became the lead portfolio manager for the Quantum fund and its Chief Investment Officer, and although his Bank of England trade made them $1 billion, he left Soros’ firm as the Dot Com bubble popped.

Later, he pivoted to managing his own fund, Duquesne Capital Management. It achieved an annual average return of 30% for 30 years, without a single losing year.

This billionaire may not be in the spotlight, but he is still investing and managing to outperform the market. Druckenmiller is currently betting big on three stocks that are rare to find in the portfolios of any other billionaire, at least not this high up. All three are biotech plays.

#3 Holding: Teva Pharmaceutical Industries (TEVA)

Teva Pharmaceutical is an Israeli company that is now the largest generic drug manufacturer in the world. TEVA stock performed poorly in the past, but Druckenmiller has been scooping up the stock as it traded at a discounted valuation.

These bets have played out well, with TEVA stock up 58.11% in the past six months alone. The company has reduced its debt signiifcantly and Druckenmiller likely sees a full rebound.

Druckenmiller owns $335.2 million worth of TEVA stock, constituting 8.53% of his portfolio. He has increased his holdings here by 3.91%.

#2 Holding: Insmed (INSM)

Insmed is a biopharmaceutical company that makes therapies for rare diseases, with a focus on lung issues. The stock has been one of the strongest biotech performers, up 175.02% in the last six months alone. A key factor is recent regulatory approval in the U.S. and E.U. for Brinsupri, a treatment of non-cystic fibrosis bronchiectasis (NCFB).

Druckenmiller has been aggressively boosting his stake here, worth $349 million, or 8.88% of his portfolio. He has increased his holdings by 7.54% in the past quarter.

#1 Holding: Natera (NTRA)

Natera is a genetic testing and diagnostics company based in Texas. It has non-invasive products to detect genetic abnormalities in fetuses. It also has a test to track minimal residual disease, with potential applications in tracking cancer recurrence.

The stock is up 47.76% in the past six months. Natera has been a consistent and solid growth stock that is quickly approaching profitability. However, it is in an overlooked industry and has flown under Wall Street’s radar.

The company’s products continue gaining strength, and once it becomes profitable and expands margins, more big investors may notice it. Natera is also an AI-healthcare bet due to the company using it during its genetic testing process.

Druckenmiller’s NTRA position is worth $517.44 million, or 13.16% of his portfolio. His holdings here have increased by 4.19%.

The image featured at the top of this post is ©iStock.